Aims:Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19. Methods and results: A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19. Conclusion: This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.

European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis / Baigent, C.; Windecker, S.; Andreini, D.; Arbelo, E.; Barbato, E.; Bartorelli, A. L.; Baumbach, A.; Behr, E. R.; Berti, S.; Bueno, H.; Capodanno, D.; Cappato, R.; Chieffo, A.; Collet, J.; Cuisset, T.; De Simone, G.; Delgado, V.; Dendale, P.; Dudek, D.; Edvardsen, T.; Elvan, A.; Gonzalez-Juanatey, J. R.; Gori, M.; Grobbee, D.; Guzik, T. J.; Halvorsen, S.; Haude, M.; Heidbuchel, H.; Hindricks, G.; Ibanez, B.; Karam, N.; Katus, H.; Klok, F. A.; Konstantinides, S. V.; Landmesser, U.; Leclercq, C.; Leonardi, S.; Lettino, M.; Marenzi, G.; Mauri, J.; Metra, M.; Morici, N.; Mueller, C.; Petronio, A. S.; Polovina, M. M.; Potpara, T.; Praz, F.; Prendergast, B.; Prescott, E.; Price, S.; Pruszczyk, P.; Rodriguez-Leor, O.; Roffi, M.; Romaguera, R.; Rosenkranz, S.; Sarkozy, A.; Scherrenberg, M.; Seferovic, P.; Senni, M.; Spera, F. R.; Stefanini, G.; Thiele, H.; Tomasoni, D.; Torracca, L.; Touyz, R. M.; Wilde, A. A.; Williams, B.. - In: ESC HEART FAILURE. - ISSN 2055-5822. - 43:11(2022), pp. 1033-1058. [10.1093/eurheartj/ehab696]

European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

Andreini D.;Barbato E.;Berti S.;Chieffo A.;Halvorsen S.;Metra M.;Senni M.;Stefanini G.;Touyz R. M.;
2022

Abstract

Aims:Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19. Methods and results: A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19. Conclusion: This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.
2022
ACE2; Arrhythmias; Biomarkers; Cardiogenic shock; COVID-19; Myocardial injury; Myocarditis; Non-invasive imaging
01 Pubblicazione su rivista::01a Articolo in rivista
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis / Baigent, C.; Windecker, S.; Andreini, D.; Arbelo, E.; Barbato, E.; Bartorelli, A. L.; Baumbach, A.; Behr, E. R.; Berti, S.; Bueno, H.; Capodanno, D.; Cappato, R.; Chieffo, A.; Collet, J.; Cuisset, T.; De Simone, G.; Delgado, V.; Dendale, P.; Dudek, D.; Edvardsen, T.; Elvan, A.; Gonzalez-Juanatey, J. R.; Gori, M.; Grobbee, D.; Guzik, T. J.; Halvorsen, S.; Haude, M.; Heidbuchel, H.; Hindricks, G.; Ibanez, B.; Karam, N.; Katus, H.; Klok, F. A.; Konstantinides, S. V.; Landmesser, U.; Leclercq, C.; Leonardi, S.; Lettino, M.; Marenzi, G.; Mauri, J.; Metra, M.; Morici, N.; Mueller, C.; Petronio, A. S.; Polovina, M. M.; Potpara, T.; Praz, F.; Prendergast, B.; Prescott, E.; Price, S.; Pruszczyk, P.; Rodriguez-Leor, O.; Roffi, M.; Romaguera, R.; Rosenkranz, S.; Sarkozy, A.; Scherrenberg, M.; Seferovic, P.; Senni, M.; Spera, F. R.; Stefanini, G.; Thiele, H.; Tomasoni, D.; Torracca, L.; Touyz, R. M.; Wilde, A. A.; Williams, B.. - In: ESC HEART FAILURE. - ISSN 2055-5822. - 43:11(2022), pp. 1033-1058. [10.1093/eurheartj/ehab696]
File allegati a questo prodotto
File Dimensione Formato  
ehab696.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 6.45 MB
Formato Adobe PDF
6.45 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1699869
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 95
  • ???jsp.display-item.citation.isi??? 66
social impact